secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001851734-22-000663
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen Q2 net loss $17.5M; PALISADE-2 restart after interim analysis
----------------------------------------------------------------------

- Net loss $17.5M vs $13.2M YoY; R&D spend $12.9M (+$2.9M) on PH94B/PH10 trials.
- Cash and equivalents $35.3M; shares outstanding 206.8M as of Nov 9, 2022.
- Independent interim analysis recommends continuing PALISADE-2 Phase 3 PH94B trial; restart preparations underway.
- Preliminary PALISADE Open Label data (n≈400) shows LSAS functional improvement; full assessment Q1 2023.
- IND submitted to FDA for PH10 Phase 1 study in healthy volunteers to enable Phase 2B in major depressive disorder.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000185173422000663/0001851734-22-000663-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000185173422000663/vtgn20221110_8k.htm
  HTML page:      https://secwatch.observer/filing/0001851734-22-000663

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer